In the last trading session, 1.23 million Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) shares changed hands as the company’s beta touched 1.59. With the company’s per share price at $10.71 changed hands at -$0.57 or -5.05% during last session, the market valuation stood at $1.42B. CNTA’s last price was a discount, traded about -78.24% off its 52-week high of $19.09. The share price had its 52-week low at $7.75, which suggests the last value was 27.64% up since then. When we look at Centessa Pharmaceuticals plc ADR’s average trading volume, we note the 10-day average is 1.24 million shares, with the 3-month average coming to 955.84K.
Analysts gave the Centessa Pharmaceuticals plc ADR (CNTA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended CNTA as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Centessa Pharmaceuticals plc ADR’s EPS for the current quarter is expected to be -0.28.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Instantly CNTA was in red as seen at the end of in last trading. With action -19.05%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -36.06%, with the 5-day performance at -19.05% in the red. However, in the 30-day time frame, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) is -32.22% down. Looking at the short shares, we see there were 4.86 million shares sold at short interest cover period of 4.53 days.
The consensus price target for the stock as assigned by Wall Street analysts is 27.5, meaning bulls need an upside of 61.05% from its current market value. According to analyst projections, CNTA’s forecast low is 27 with 28 as the target high. To hit the forecast high, the stock’s price needs a -161.44% plunge from its current level, while the stock would need to soar -152.1% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -210.04%. The 2025 estimates are for Centessa Pharmaceuticals plc ADR earnings to increase by 29.13%, but the outlook for the next 5-year period is at 6.48% per year.
CNTA Dividends
Centessa Pharmaceuticals plc ADR is expected to release its next quarterly earnings report on 2025-Mar-23.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.54% of Centessa Pharmaceuticals plc ADR shares while 93.19% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 94.65%. There are 93.19% institutions holding the Centessa Pharmaceuticals plc ADR stock share, with MEDICXI VENTURES MANAGEMENT (JERSEY) LTD the top institutional holder. As of 2024-06-30, the company held 18.233% of the shares, roughly 19.96 million CNTA shares worth $180.27 million.
GENERAL ATLANTIC, L.P. holds the second largest percentage of outstanding shares, with 8.8427% or 9.68 million shares worth $87.43 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were T. Rowe Price Health Sciences Fund, Inc. and Fidelity Select Portfolios-Biotechnology Portfolio . With 3.48 shares estimated at $37.23 million under it, the former controlled 2.61% of total outstanding shares. On the other hand, Fidelity Select Portfolios-Biotechnology Portfolio held about 2.23% of the shares, roughly 2.98 shares worth around $31.88 million.
